We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarkers Promising for Detecting Early Ovarian Cancer

By HospiMedica staff writers
Posted on 14 Apr 2004
Scientists are working with two biomarkers associated with ovarian cancer cells to develop a new test for the early detection of ovarian cancer.

Ovarian cancer is not usually diagnosed until it is too late for treatment to be effective. More...
A test that could detect the cancer at an early stage could help to save the lives of many women. The new biomarkers show promise as the basis for a blood test that would be able to detect early ovarian cancer. This research is being conducted by scientists at Fujirebio Diagnostics, Inc. (Malvern, PA, USA), which licensed the biomarkers from the Pacific Northwest Research Institute (Seattle, WA, USA).

Fujirebio developed the best currently available diagnostic test for ovarian cancer, CA125. While it is useful in diagnosing late-stage cancers and detecting the recurrence of tumors after chemotherapy and radiation, it is not very effective in identifying early-stage disease. Sometimes, it also indicates the presence of ovarian cancer where there is none. Such false-positives lead to dangerous, expensive, and unnecessary treatment.

Because the biomarkers associated with ovarian cancer, HE4 and mesothilin, are molecules secreted readily into the blood, their presence should be detectable if a simple and inexpensive blood test can be developed. In a study reported in the July 1, 2003, issue of Cancer Research, HE4 proved to be at least as effective as CA125. When no false-positive results occurred, HE4's sensitivity to ovarian carcinoma was 40% higher than that of CA 125.

The survival statistics for ovarian cancer are dismal, according to the American Cancer Society. Three out of four cases of ovarian cancer are diagnosed in late stages. Last year, 14,000 women died of the disease in the United States alone.

"Unfortunately, ovarian carcinoma is most often diagnosed when it is already in an advanced stage. Even after surgery and chemotherapy, relapses are common,” noted Dr. Ingegerd Hellstrom, a principal scientist at PNRI and the lead author of the article in Cancer Research.

Fujirebio is a leading producer of tumor marker assays. The company was formerly called Centecor Diagnostics, which was acquired in 1998 by Fujirebio, Inc. of Tokyo, Japan.




Related Links:
Fujirebio
PNRI

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Tourniquet System
heidi– mein Tourniquet
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new, inexpensive stick-on sweat sensor measures lipid levels, offering a noninvasive way to continuously monitor cholesterol and triglycerides. (Image Credit: California Institute of Technology)

Wearable Patch Enables Continuous Noninvasive Cholesterol and Triglyceride Monitoring

Cholesterol and triglyceride testing typically relies on phlebotomy and intermittent lipid panels, limiting real-time assessment of cardiovascular and metabolic risk. Noninvasive monitoring could reduce... Read more

Surgical Techniques

view channel
Image: Phasix Mesh is a fully resorbable monofilament scaffold designed for rapid tissue incorporation, combining synthetic mesh repair strength with biologic graft-like remodeling. (Photo courtesy of BD)

Resorbable Mesh Evaluated to Prevent Incisional Hernias After Abdominal Surgery

Incisional hernia is a common complication after abdominal surgery and can necessitate additional interventions and prolonged recovery. Preventive strategies remain limited, and there are currently no... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.